High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
about
Inflammatory etiopathogenesis of systemic lupus erythematosus: an updateIntracellular nucleic acid sensors and autoimmunityThe dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunityAnti-high Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lpr Lupus-Prone Mice.HMGB1 in health and disease.Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.Urinary levels of high mobility group box-1 are associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitisHMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK CellsSkin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative GroupsHMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis.Neutrophil extracellular traps in sterile inflammation: the story after dying?Cardiovascular disease and high-mobility group box 1--is a new inflammatory killer in town?Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases.The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus.The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.Complexity of danger: the diverse nature of damage-associated molecular patterns.HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarminsMembers of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis.High-mobility group box 1 inhibits gastric ulcer healing through Toll-like receptor 4 and receptor for advanced glycation end products.Lupus nephritis - alarmins may sound the alarm?Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice.Post-translational modifications of high mobility group box 1 and cancer.Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?Neutrophil Extracellular Traps Are Pathogenic in Ventilator-Induced Lung Injury and Partially Dependent on TLR4.Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series).Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis.
P2860
Q26796413-7A25E97B-08FD-457C-9E44-5DE6172CDB37Q26997316-00DE8D17-43F2-47CA-8F70-FA4C311A83C4Q28384138-AB985C44-6457-48C8-822A-080913ED2941Q33802812-004D685D-7832-4B73-9BD7-92885A46FFB2Q34622835-C43A66A1-02E4-4E37-877E-66472687D222Q35140467-BFF1AC4D-CDF4-46D1-84B6-F93F064144C3Q35465240-5A44C210-90C5-4299-B668-5281A817AFC7Q35922101-EC60DC44-058D-466C-A0E0-F5E4C9C54F1AQ35924733-E68BA492-D05C-4939-AF02-B2010CD75AF2Q36699968-476D455A-DDEA-4C38-93A7-C5CE8828DCF6Q37980498-94D91200-F6E3-459F-B194-0AC56F2AF1AEQ38038666-E1FAFEE4-014E-4D2B-A14E-86FD67589927Q38040046-9C5282A9-9F64-48A7-8080-AFF80F5743B0Q38068181-730942BB-019C-494F-8340-8E4BFC51A333Q38131032-4C92A1B0-8790-44A0-B160-C9DADA02B724Q38209945-BC77A7AD-5566-4220-B2EE-3255C8AA74CFQ38267715-B67E2D90-89F7-4902-B5D0-869F9B78FCB6Q38939435-982A3632-851D-4387-9824-A523E1A4A68EQ39095935-626C5DF5-ADE5-493C-AAB0-946451A8C894Q40432262-90D75A6F-39D7-438E-8E91-D15D967CDA2EQ42913346-DA96F87C-2045-42AE-A4A3-C27450F9C4F4Q43137597-A08FF2E1-06DC-470C-BB7D-3E8226809419Q45090317-A85ACF7C-A9E4-466F-AD67-1CCCFCAD8B05Q47220872-06F784C4-3910-496E-BD17-7F8159C0E83CQ47258530-658F81F9-38D0-4E40-921D-439F17BB508AQ48128888-D4EA217C-E41D-434B-BA0F-F1F0EAB2BF2EQ52685710-D24DC171-1E9A-4C7E-9B95-F05EE0D56484Q54293005-234D35B6-3DB7-4354-B2A6-42B2138491EC
P2860
High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@ast
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@en
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@nl
type
label
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@ast
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@en
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@nl
prefLabel
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@ast
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@en
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@nl
P2860
P1476
High-mobility group box 1 repr ...... systemic lupus erythematosus.
@en
P2093
V Urbonaviciute
P2860
P304
P356
10.1111/J.1365-2796.2011.02432.X
P407
P577
2011-10-01T00:00:00Z